Guardant Health Inc. is a leading precision oncology company based in Redwood City, California. Established in 2012, Guardant Health is at the forefront of developing advanced technologies for cancer detection and monitoring. The company specializes in liquid biopsy solutions, utilizing blood-based tests to analyze circulating tumor DNA (ctDNA) and other biomarkers. This approach provides a non-invasive and comprehensive way to assess cancer genetics, guiding treatment decisions and monitoring disease progression.
Guardant Health's flagship product is Guardant360, a liquid biopsy test designed to detect genomic alterations in a wide range of solid tumors. The test enables oncologists to identify specific mutations and alterations in the patient's cancer, aiding in the selection of targeted therapies. The company's commitment to precision oncology is exemplified by its efforts to provide personalized and data-driven solutions for cancer patients.
In addition to Guardant360, the company has expanded its portfolio to include other liquid biopsy tests, such as GuardantOMNI and GuardantIDx. GuardantOMNI is a broader genomic profiling test, while GuardantIDx is focused on early cancer detection and recurrence monitoring. These tests contribute to Guardant Health's goal of advancing cancer care through innovative and accessible diagnostic solutions.
Guardant Health has established partnerships with various healthcare providers, biopharmaceutical companies, and research institutions to further enhance its impact in the field of precision oncology. The company's collaborations aim to accelerate the development of new therapies, validate its liquid biopsy technologies, and expand access to genomic information for cancer patients.